Can a new PET tracer reveal a key cancer target?

NCT ID NCT06719856

Recruiting now Diagnosis Sponsor: Peking University Cancer Hospital & Institute Source: ClinicalTrials.gov ↗

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This trial is testing whether a new PET imaging agent can safely and effectively detect a protein called MMP14 on solid tumors. The study will involve about 30 adults with various solid tumors, such as melanoma, lung, or breast cancer. Each participant will receive the experimental tracer and undergo a PET/CT scan to measure how much of it accumulates in tumor lesions. The goal is to see if this imaging approach could help identify patients who might benefit from treatments that target MMP14.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: A 68Ga-labeled bicyclic peptide radiotracer targeting MMP14, used for PET imaging
What this could lead to: If successful, this imaging method could help identify patients whose tumors express MMP14, making them candidates for targeted treatments.
What could go wrong: This is an early-stage imaging trial with a small number of participants, so the tracer may not reliably detect MMP14 in all tumor types, and results may not generalize.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Beijing Cancer Hospital
RECRUITING

Beijing, Beijing Municipality, 100142, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.